KUALA LUMPUR, March 7 (Bernama) -- Zenas BioPharma, a global biopharmaceutical company has appointed Patricia Allen to its Board of Directors, in which she also will serve as Chairperson of the Audit Committee.
Its Founder and Chief Executive Officer, Lonnie Moulder said Allen has successfully led cross-organisational functions and served on the board of directors of both private and public global biotechnology companies.
“We look forward to Patty’s contributions to the next phase of Zenas’ growth as we advance our mission to develop and commercialise transformative immunology-based therapies for patients in need,” he said in a statement.
Meanwhile, Allen said she looked forward to collaborating with the experienced Zenas team and Board of Directors, who are building a leading of inflammation and immunology-focused global biopharmaceutical company through disciplined pipeline execution and business development.
Allen joins the Zenas Board of Directors with over 20 years of experience leading finance, investor relations, business development, human resources, operations and information technology at global public as well as private biotechnology companies.
Most recently, she served as the Chief Financial Officer at Vividion Therapeutics, from where she recently retired.
Currently, Allen serves on the board of directors and as chair of the audit committee of Deciphera Pharmaceuticals, SwanBio Therapeutics and Anokion, in addition to holding past board member and audit committee chair roles at Inversago Pharma and Yumanity Therapeutics.
-- BERNAMA
No comments:
Post a Comment